Prednisolone Acetate
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
- Prednisolone Acetate
- Prednisolone Acetate: From Uveitis and Conjunctivitis to Chronic Follicular Conjunctivitis
Prednisolone Acetate: From Uveitis and Conjunctivitis to Chronic Follicular Conjunctivitis
One-Sentence Summary
Prednisolone acetate is a topical corticosteroid originally used for ocular inflammation such as uveitis and conjunctivitis. The TxGNN model predicts it may be effective for chronic follicular conjunctivitis (top-ranked prediction), but no clinical trials or publications currently support this specific prediction. Among the other top-10 predictions, only papillary conjunctivitis and vernal conjunctivitis have any indirect supporting evidence.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Uveitis, iris disease, ciliary body disease, panuveitis, conjunctivitis, iridocyclitis and related ocular inflammatory conditions (the licence record has no approved indication text, so this is taken from knowledge-graph indication data) |
| Predicted New Indication | Chronic follicular conjunctivitis |
| TxGNN Prediction Score | 99.74% |
| Evidence Level | L5 (model prediction only) |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 1 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, prednisolone acetate is a topical ophthalmic corticosteroid. Its efficacy in ocular inflammation, including uveitis and conjunctivitis, is established, and mechanistically it may be applicable to chronic follicular conjunctivitis. Corticosteroids generally suppress ocular surface inflammation.
The predicted disease sits in the same family as the conjunctivitis conditions already linked to this drug, which explains the high score. However, the prediction is based on the model alone. Chronic follicular conjunctivitis has a range of causes (infectious, toxic, allergic), and a steroid is not appropriate for all of them.
Other high-scoring predictions follow the same pattern. Several are conjunctival diseases (serous conjunctivitis, conjunctival folliculosis, Angelucci syndrome) with only a plausible anti-inflammatory rationale and no evidence. Others are poor fits: parasitic and acute hemorrhagic (viral) conjunctivitis carry a risk of worsening infection, and postinfectious vasculitis is a systemic disease that a topical eye drop is unlikely to reach.
Clinical Trial Evidence
No clinical trials are registered for the top-ranked prediction, chronic follicular conjunctivitis. The trials below relate to other predicted conjunctival indications and are indirect.
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT01437982 | Phase 4 | Completed | 140 | Post-marketing safety surveillance of loteprednol (a different corticosteroid) 0.5% suspension. Relevant to papillary conjunctivitis only indirectly, and the condition studied is not confirmed. |
| NCT04705584 | N/A | Unknown | 180 | Cyclosporine A 2% vs tacrolimus 0.3% in resistant spring catarrh (vernal conjunctivitis), as an alternative to steroids. Steroids are described as the cornerstone therapy but carry glaucoma and cataract risks. |
Literature Evidence
No publications were found for chronic follicular conjunctivitis. The most relevant items for other predicted conditions are listed below. Most concern other drugs.
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 24055903 | 2013 | RCT (experimental model) | Cornea | Compared cyclosporine A, epinastine and prednisolone acetate 1% in an experimental allergic conjunctivitis model. |
| 12931748 | 2003 | Cohort | Asian Pac J Allergy Immunol | Vernal keratoconjunctivitis in Thailand. Severe cases were given topical corticosteroids. |
| 26984315 | 2016 | Review | Advances in Therapy | Topical corticosteroids (loteprednol) and the risk of raised intraocular pressure. |
| 18020605 | 1998 | Review | BioDrugs | Loteprednol etabonate for ocular inflammation. |
| 9713785 | 1998 | Cohort | J Glaucoma | Intraocular pressure changes with long-term loteprednol use. It was effective in giant papillary conjunctivitis, allergic conjunctivitis and uveitis. |
| 15523196 | 2004 | Review | Curr Opin Ophthalmol | Ocular manifestations and management of graft-versus-host disease (pseudomembranous conjunctivitis context). |
| 32621983 | 2020 | Case report | J AAPOS | Mycoplasma-induced rash and mucositis with pseudomembranes, treated with topical prednisolone acetate among other agents. |
| 21434554 | 2011 | Case report | Indian J Tuberc | Conjunctival tuberculosis initially misdiagnosed as allergic conjunctivitis and treated with prednisolone acetate 1%, with no improvement. This is a caution against steroid use without a confirmed diagnosis. |
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN04661P | PRED FORTE OPHTHALMIC SUSPENSION 1% (Allergan Pharmaceuticals Ireland) | Solution | Not stated in the licence record |
Safety Considerations
- Class concern (from the literature): Prolonged topical corticosteroid use can raise intraocular pressure and lead to glaucoma, and may cause cataract. This matters for chronic conditions such as vernal conjunctivitis.
- Conditions flagged as contraindications in the knowledge graph (not label text): herpes simplex virus keratitis, viral eye infection, fungal infection of eye, ocular tuberculosis, eye infectious disease, open-angle glaucoma, ocular hypertension, and corneal pigmentation. The graph also lists several systemic conditions (e.g. diabetes mellitus, diabetic ketoacidosis, porphyria, G6PD deficiency, glycogen storage disease, cystinuria, galactosemia), which should be verified against the product label.
- Drug interactions: No interaction data were found.
Please refer to the package insert for full warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The top-ranked prediction, chronic follicular conjunctivitis, rests on a model score alone (L5) with no trials or literature. Because the drug is already registered for conjunctivitis, the mechanism is plausible. Still, the cause of chronic follicular conjunctivitis matters, since steroids can worsen infectious causes. Papillary and vernal conjunctivitis (L4) are better candidates for further research, but the evidence concerns other drugs (loteprednol, cyclosporine) and is indirect.
To proceed, the following is needed:
- Package insert warnings and contraindications for the Singapore-registered product
- Mechanism of action data for prednisolone acetate
- Studies of prednisolone acetate specifically in chronic follicular, papillary or vernal conjunctivitis
- Clarification of the aetiology (allergic, toxic, infectious) in which a steroid would be appropriate
- An intraocular pressure and infection-exclusion monitoring plan for any extended use
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.